Cargando…

Association between prostate cancer characteristics and BRCA1/2-associated family cancer history in a Japanese cohort

In addition to breast, ovarian, and pancreatic cancers, BRCA1/2 genes have been associated with prostate cancer (PC). However, the role of BRCA1/2-associated family cancer history (FCH) has remained unexplored in treating these four cancer types as a homogenous pathophysiological group. We aimed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishiyama, Yudai, Shimbo, Masaki, Iizuka, Junpei, Deshpande, Gautam, Tanabe, Kazunari, Hattori, Kazunori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7755278/
https://www.ncbi.nlm.nih.gov/pubmed/33351846
http://dx.doi.org/10.1371/journal.pone.0244149
_version_ 1783626325066514432
author Ishiyama, Yudai
Shimbo, Masaki
Iizuka, Junpei
Deshpande, Gautam
Tanabe, Kazunari
Hattori, Kazunori
author_facet Ishiyama, Yudai
Shimbo, Masaki
Iizuka, Junpei
Deshpande, Gautam
Tanabe, Kazunari
Hattori, Kazunori
author_sort Ishiyama, Yudai
collection PubMed
description In addition to breast, ovarian, and pancreatic cancers, BRCA1/2 genes have been associated with prostate cancer (PC). However, the role of BRCA1/2-associated family cancer history (FCH) has remained unexplored in treating these four cancer types as a homogenous pathophysiological group. We aimed to clarify the relationship between BRCA1/2-associated FCH and PC, and to assess its relationship with cancer aggressiveness. Patient characteristics, positive family history of BRCA1/2-associated cancer, and cancer characteristics (Gleason score, prostate specific antigen level at diagnosis, and clinical tumor stage) were analyzed. Among the 1,985 eligible candidates, 473 (23.83%) patients had adequately detailed FCH, obtained via questionnaire, and were thus included in the study. BRCA1/2-associated FCH was observed in 135 (28.54%) patients with PC (68, 14.38%), breast (44, 9.30%), pancreatic (31, 6.55%), or ovarian (8, 1.69%) cancers. BRCA1/2-associated FCH was not significantly associated with high Gleason score (≥ 8). Patients with BRCA-associated FCH were less likely to present with high clinical tumor stage, and no difference was observed in prostate-specific antigen level, presence of metastatic lesions at diagnosis, or likelihood of high-risk classification between patients with and without BRCA-associated FCH. This is the first report of BRCA1/2-associated FCH in Japanese men, indicating that family history did not affect the severity or aggressiveness of PC.
format Online
Article
Text
id pubmed-7755278
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-77552782021-01-06 Association between prostate cancer characteristics and BRCA1/2-associated family cancer history in a Japanese cohort Ishiyama, Yudai Shimbo, Masaki Iizuka, Junpei Deshpande, Gautam Tanabe, Kazunari Hattori, Kazunori PLoS One Research Article In addition to breast, ovarian, and pancreatic cancers, BRCA1/2 genes have been associated with prostate cancer (PC). However, the role of BRCA1/2-associated family cancer history (FCH) has remained unexplored in treating these four cancer types as a homogenous pathophysiological group. We aimed to clarify the relationship between BRCA1/2-associated FCH and PC, and to assess its relationship with cancer aggressiveness. Patient characteristics, positive family history of BRCA1/2-associated cancer, and cancer characteristics (Gleason score, prostate specific antigen level at diagnosis, and clinical tumor stage) were analyzed. Among the 1,985 eligible candidates, 473 (23.83%) patients had adequately detailed FCH, obtained via questionnaire, and were thus included in the study. BRCA1/2-associated FCH was observed in 135 (28.54%) patients with PC (68, 14.38%), breast (44, 9.30%), pancreatic (31, 6.55%), or ovarian (8, 1.69%) cancers. BRCA1/2-associated FCH was not significantly associated with high Gleason score (≥ 8). Patients with BRCA-associated FCH were less likely to present with high clinical tumor stage, and no difference was observed in prostate-specific antigen level, presence of metastatic lesions at diagnosis, or likelihood of high-risk classification between patients with and without BRCA-associated FCH. This is the first report of BRCA1/2-associated FCH in Japanese men, indicating that family history did not affect the severity or aggressiveness of PC. Public Library of Science 2020-12-22 /pmc/articles/PMC7755278/ /pubmed/33351846 http://dx.doi.org/10.1371/journal.pone.0244149 Text en © 2020 Ishiyama et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Ishiyama, Yudai
Shimbo, Masaki
Iizuka, Junpei
Deshpande, Gautam
Tanabe, Kazunari
Hattori, Kazunori
Association between prostate cancer characteristics and BRCA1/2-associated family cancer history in a Japanese cohort
title Association between prostate cancer characteristics and BRCA1/2-associated family cancer history in a Japanese cohort
title_full Association between prostate cancer characteristics and BRCA1/2-associated family cancer history in a Japanese cohort
title_fullStr Association between prostate cancer characteristics and BRCA1/2-associated family cancer history in a Japanese cohort
title_full_unstemmed Association between prostate cancer characteristics and BRCA1/2-associated family cancer history in a Japanese cohort
title_short Association between prostate cancer characteristics and BRCA1/2-associated family cancer history in a Japanese cohort
title_sort association between prostate cancer characteristics and brca1/2-associated family cancer history in a japanese cohort
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7755278/
https://www.ncbi.nlm.nih.gov/pubmed/33351846
http://dx.doi.org/10.1371/journal.pone.0244149
work_keys_str_mv AT ishiyamayudai associationbetweenprostatecancercharacteristicsandbrca12associatedfamilycancerhistoryinajapanesecohort
AT shimbomasaki associationbetweenprostatecancercharacteristicsandbrca12associatedfamilycancerhistoryinajapanesecohort
AT iizukajunpei associationbetweenprostatecancercharacteristicsandbrca12associatedfamilycancerhistoryinajapanesecohort
AT deshpandegautam associationbetweenprostatecancercharacteristicsandbrca12associatedfamilycancerhistoryinajapanesecohort
AT tanabekazunari associationbetweenprostatecancercharacteristicsandbrca12associatedfamilycancerhistoryinajapanesecohort
AT hattorikazunori associationbetweenprostatecancercharacteristicsandbrca12associatedfamilycancerhistoryinajapanesecohort